Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.56 |
| ▸ | TACR1 | P25103 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231318 | 0.89 | DPP4 (0.57) | DPP4TACR1CYP2C9RORARORC | |
| Hydrochloric Acid SCHEMBL5239841 | 0.87 | DPP4 (0.71) | DPP4TACR1CYP2C9RORARORC | |
| SCHEMBL5240910 | 0.87 | DPP4 (0.59) | DPP4TACR1MAPK8KCNA5KCNH2 | |
| SCHEMBL5238106 | 0.85 | DPP4 (0.53) | DPP4TACR1 | |
| SCHEMBL8787724 | 0.84 | DPP4 (0.77) | DPP4TACR1MAPK8KCNA5KCNH2 | |
| SCHEMBL6107908 | 0.83 | TACR1 (0.54) | DPP4TACR1KCNA5KCNH2 | |
| SCHEMBL5240310 | 0.82 | DPP4 (0.57) | DPP4MAPK8KCNA5KCNH2 | |
| SCHEMBL5234162 | 0.82 | DPP4 (0.54) | DPP4TACR1CYP2C9 | |
| SCHEMBL5233313 | 0.81 | TACR1 (0.61) | DPP4TACR1CYP2C9MAPK8 | |
| SCHEMBL5237400 | 0.79 | DPP4 (0.69) | DPP4TACR1MAPK8KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1355886-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062764-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885TACR1 1624/4885CYP2C9 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.